论文部分内容阅读
目的 探讨乳腺癌DNA倍体与ER的相关性和生物学行为。方法 本文应用流式细胞术(FCM)检测了30例乳腺癌的细胞核DNA含量,同时用免疫组化PAP法测定了肿瘤细胞中雌激素受体(ER)的表达,以探讨其二者的相关性和生物学行为。结果 乳腺癌DNA含量63.3％(19/30)为异倍体,37.7％(11/30)为二倍体或近二倍体。DNA含量与ER呈负相关(P<0.01)。异倍体在ER阳性者达78.57％(11/14)。结论 DNA含量与临床分期相关性显著,即与肿瘤大小,分化程度及预后相关密切。也提示ER表达DNA含量有一定相关性。DNA含量是反应肿瘤生物学行为较正确、客观的生物学指标。
Objective To explore the correlation and biological behavior of DNA ploidy and ER in breast cancer. Methods Flow cytometry (FCM) was used to detect the nuclear DNA content in 30 cases of breast cancer. Meanwhile, the expression of estrogen receptor (ER) in tumor cells was measured by immunohistochemical PAP method to explore the correlation between them. Sexual and biological behavior. Results The DNA content of breast cancer was 63.3% (19/30) aneuploid, and 37.7% (11/30) was diploid or nearly diploid. DNA content was negatively correlated with ER (P<0.01). The heteroploid was 78.57% (11/14) positive in ER. Conclusion The correlation between DNA content and clinical stage is significant, which is closely related to tumor size, differentiation and prognosis. It also suggests that ER expression DNA content has a certain correlation. DNA content is a relatively correct and objective biological indicator of the biological behavior of tumors.